CA3082095A1 - A combination therapy with apatinib for the treatment of cancer - Google Patents

Info

Publication number

CA3082095A1

CA3082095A1 CA3082095A CA3082095A CA3082095A1 CA 3082095 A1 CA3082095 A1 CA 3082095A1 CA 3082095 A CA3082095 A CA 3082095A CA 3082095 A CA3082095 A CA 3082095A CA 3082095 A1 CA3082095 A1 CA 3082095A1

Authority

CA

Canada

Prior art keywords

administered

amount

rivoceranib

cancer

nivolumab

Prior art date

2017-11-10

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 title claims abstract description 310
• 229960003982 apatinib Drugs 0.000 title claims abstract description 309
• 206010028980 Neoplasm Diseases 0.000 title claims abstract description 187
• 201000011510 cancer Diseases 0.000 title claims abstract description 124
• 238000011282 treatment Methods 0.000 title claims abstract description 69
• 238000002648 combination therapy Methods 0.000 title description 40
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims abstract description 325
• 239000005483 tyrosine kinase inhibitor Substances 0.000 claims abstract description 325
• 239000002955 immunomodulating agent Substances 0.000 claims abstract description 226
• 238000000034 method Methods 0.000 claims abstract description 187
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 318
• 229960003301 nivolumab Drugs 0.000 claims description 284
• 229960002621 pembrolizumab Drugs 0.000 claims description 278
• FYJROXRIVQPKRY-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic acid Chemical group CS(O)(=O)=O.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 FYJROXRIVQPKRY-UHFFFAOYSA-N 0.000 claims description 138
• 150000003839 salts Chemical class 0.000 claims description 122
• 239000003826 tablet Substances 0.000 claims description 73
• 239000003112 inhibitor Substances 0.000 claims description 31
• 230000003902 lesion Effects 0.000 claims description 31
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 28
• 239000012270 PD-1 inhibitor Substances 0.000 claims description 23
• 239000012668 PD-1-inhibitor Substances 0.000 claims description 23
• 229940121655 pd-1 inhibitor Drugs 0.000 claims description 23
• 230000002829 reductive effect Effects 0.000 claims description 22
• 206010009944 Colon cancer Diseases 0.000 claims description 21
• 229960000106 biosimilars Drugs 0.000 claims description 21
• 239000002775 capsule Substances 0.000 claims description 21
• 239000007788 liquid Substances 0.000 claims description 18
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 17
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 17
• 201000009030 Carcinoma Diseases 0.000 claims description 15
• 239000000843 powder Substances 0.000 claims description 14
• 206010039491 Sarcoma Diseases 0.000 claims description 12
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 11
• 208000029742 colonic neoplasm Diseases 0.000 claims description 11
• 208000014018 liver neoplasm Diseases 0.000 claims description 11
• 206010005003 Bladder cancer Diseases 0.000 claims description 10
• 208000026310 Breast neoplasm Diseases 0.000 claims description 10
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 10
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 10
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
• 206010033128 Ovarian cancer Diseases 0.000 claims description 10
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 10
• 108091008605 VEGF receptors Proteins 0.000 claims description 10
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 10
• 238000001990 intravenous administration Methods 0.000 claims description 10
• 201000007270 liver cancer Diseases 0.000 claims description 10
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 10
• 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims description 10
• 206010038389 Renal cancer Diseases 0.000 claims description 9
• 206010041067 Small cell lung cancer Diseases 0.000 claims description 9
• 238000007918 intramuscular administration Methods 0.000 claims description 9
• 201000010982 kidney cancer Diseases 0.000 claims description 9
• 235000019359 magnesium stearate Nutrition 0.000 claims description 9
• 208000000587 small cell lung carcinoma Diseases 0.000 claims description 9
• 206010041823 squamous cell carcinoma Diseases 0.000 claims description 9
• 238000007920 subcutaneous administration Methods 0.000 claims description 9
• 239000002118 L01XE12 - Vandetanib Substances 0.000 claims description 8
• 206010025323 Lymphomas Diseases 0.000 claims description 8
• 208000006265 Renal cell carcinoma Diseases 0.000 claims description 8
• 208000032839 leukemia Diseases 0.000 claims description 8
• 201000001441 melanoma Diseases 0.000 claims description 8
• 238000007911 parenteral administration Methods 0.000 claims description 8
• 206010044412 transitional cell carcinoma Diseases 0.000 claims description 8
• 229960000241 vandetanib Drugs 0.000 claims description 8
• UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 8
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 7
• 206010006187 Breast cancer Diseases 0.000 claims description 7
• 206010014733 Endometrial cancer Diseases 0.000 claims description 7
• 206010014759 Endometrial neoplasm Diseases 0.000 claims description 7
• 208000017604 Hodgkin disease Diseases 0.000 claims description 7
• 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 7
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 7
• 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 7
• 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 7
• 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 7
• 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
• 206010060862 Prostate cancer Diseases 0.000 claims description 7
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 7
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 7
• 229960003784 lenvatinib Drugs 0.000 claims description 7
• WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims description 7
• 208000020816 lung neoplasm Diseases 0.000 claims description 7
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
• 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
• 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
• 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
• 201000002528 pancreatic cancer Diseases 0.000 claims description 7
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
• CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 7
• 229960000639 pazopanib Drugs 0.000 claims description 7
• 229960003787 sorafenib Drugs 0.000 claims description 7
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 7
• 229960001796 sunitinib Drugs 0.000 claims description 7
• 201000002510 thyroid cancer Diseases 0.000 claims description 7
• 208000023747 urothelial carcinoma Diseases 0.000 claims description 7
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 6
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 6
• 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 6
• 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 6
• 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 6
• 239000002145 L01XE14 - Bosutinib Substances 0.000 claims description 6
• 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 6
• 239000002138 L01XE21 - Regorafenib Substances 0.000 claims description 6
• 239000002137 L01XE24 - Ponatinib Substances 0.000 claims description 6
• 229920000881 Modified starch Polymers 0.000 claims description 6
• 229920003081 Povidone K 30 Polymers 0.000 claims description 6
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
• 229960003005 axitinib Drugs 0.000 claims description 6
• RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 6
• 201000000053 blastoma Diseases 0.000 claims description 6
• UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims description 6
• 229960003736 bosutinib Drugs 0.000 claims description 6
• 201000010881 cervical cancer Diseases 0.000 claims description 6
• 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 6
• KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 6
• 229960005061 crizotinib Drugs 0.000 claims description 6
• 229960002448 dasatinib Drugs 0.000 claims description 6
• 201000008184 embryoma Diseases 0.000 claims description 6
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 6
• 229960002584 gefitinib Drugs 0.000 claims description 6
• 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 6
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 6
• 229960002411 imatinib Drugs 0.000 claims description 6
• 201000005202 lung cancer Diseases 0.000 claims description 6
• 229960004378 nintedanib Drugs 0.000 claims description 6
• XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims description 6
• 201000002628 peritoneum cancer Diseases 0.000 claims description 6
• PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims description 6
• 229960001131 ponatinib Drugs 0.000 claims description 6
• 229960004836 regorafenib Drugs 0.000 claims description 6
• FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims description 6
• 229920003109 sodium starch glycolate Polymers 0.000 claims description 6
• 239000008109 sodium starch glycolate Substances 0.000 claims description 6
• 229940079832 sodium starch glycolate Drugs 0.000 claims description 6
• 229950007213 spartalizumab Drugs 0.000 claims description 6
• AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 claims description 5
• RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 claims description 5
• 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 5
• 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 5
• 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 5
• 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 5
• 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 5
• 239000004012 Tofacitinib Substances 0.000 claims description 5
• 229960001611 alectinib Drugs 0.000 claims description 5
• KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 claims description 5
• 229950004272 brigatinib Drugs 0.000 claims description 5
• 229960001602 ceritinib Drugs 0.000 claims description 5
• VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims description 5
• 229960002465 dabrafenib Drugs 0.000 claims description 5
• BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 5
• 201000003914 endometrial carcinoma Diseases 0.000 claims description 5
• 229960001433 erlotinib Drugs 0.000 claims description 5
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 5
• 239000007941 film coated tablet Substances 0.000 claims description 5
• 230000002440 hepatic effect Effects 0.000 claims description 5
• 229960001507 ibrutinib Drugs 0.000 claims description 5
• XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 5
• 229960004891 lapatinib Drugs 0.000 claims description 5
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 5
• HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 5
• 229960001346 nilotinib Drugs 0.000 claims description 5
• 229960003278 osimertinib Drugs 0.000 claims description 5
• DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims description 5
• AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims description 5
• 229960004390 palbociclib Drugs 0.000 claims description 5
• 239000008188 pellet Substances 0.000 claims description 5
• 238000001959 radiotherapy Methods 0.000 claims description 5
• 229950003687 ribociclib Drugs 0.000 claims description 5
• 229960000215 ruxolitinib Drugs 0.000 claims description 5
• HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 5
• 208000017572 squamous cell neoplasm Diseases 0.000 claims description 5
• UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 5
• 229960001350 tofacitinib Drugs 0.000 claims description 5
• 229960004066 trametinib Drugs 0.000 claims description 5
• LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 5
• 229960003862 vemurafenib Drugs 0.000 claims description 5
• GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 5
• SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 claims description 4
• WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims description 4
• 239000005461 Canertinib Substances 0.000 claims description 4
• WVXNSAVVKYZVOE-UHFFFAOYSA-N DCC-2036 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=C4C=CC=NC4=CC=3)=CC=2)=C1 WVXNSAVVKYZVOE-UHFFFAOYSA-N 0.000 claims description 4
• 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 4
• XKFTZKGMDDZMJI-HSZRJFAPSA-N N-[5-[(2R)-2-methoxy-1-oxo-2-phenylethyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methyl-1-piperazinyl)benzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 XKFTZKGMDDZMJI-HSZRJFAPSA-N 0.000 claims description 4
• 229960001686 afatinib Drugs 0.000 claims description 4
• ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical group N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 4
• 229950002826 canertinib Drugs 0.000 claims description 4
• OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 claims description 4
• 229950002966 danusertib Drugs 0.000 claims description 4
• 208000021039 metastatic melanoma Diseases 0.000 claims description 4
• 229950008835 neratinib Drugs 0.000 claims description 4
• 229960003407 pegaptanib Drugs 0.000 claims description 4
• 229950007043 rebastinib Drugs 0.000 claims description 4
• WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims description 4
• 229960000940 tivozanib Drugs 0.000 claims description 4
• YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims description 4
• 229950000578 vatalanib Drugs 0.000 claims description 4
• BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 claims description 4
• 229960004449 vismodegib Drugs 0.000 claims description 4
• 238000002595 magnetic resonance imaging Methods 0.000 claims description 3
• 238000003325 tomography Methods 0.000 claims description 3
• 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims 2
• ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 79
• 201000010099 disease Diseases 0.000 abstract description 60
• -1 small molecule tyrosine kinase inhibitor Chemical class 0.000 description 37
• 239000000203 mixture Substances 0.000 description 36
• 150000001875 compounds Chemical class 0.000 description 26
• 238000002560 therapeutic procedure Methods 0.000 description 26
• 208000005718 Stomach Neoplasms Diseases 0.000 description 24
• 230000000694 effects Effects 0.000 description 24
• 206010017758 gastric cancer Diseases 0.000 description 24
• 239000008194 pharmaceutical composition Substances 0.000 description 24
• 201000011549 stomach cancer Diseases 0.000 description 24
• 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 20
• 208000035475 disorder Diseases 0.000 description 19
• 239000003795 chemical substances by application Substances 0.000 description 15
• 239000007787 solid Substances 0.000 description 15
• 210000004027 cell Anatomy 0.000 description 13
• 230000004083 survival effect Effects 0.000 description 13
• 230000004614 tumor growth Effects 0.000 description 13
• 241001465754 Metazoa Species 0.000 description 12
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 12
• 231100000371 dose-limiting toxicity Toxicity 0.000 description 12
• 239000003814 drug Substances 0.000 description 12
• 239000012458 free base Substances 0.000 description 12
• 239000000499 gel Substances 0.000 description 12
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 11
• 229940079593 drug Drugs 0.000 description 11
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 11
• 229960003852 atezolizumab Drugs 0.000 description 10
• 229950002916 avelumab Drugs 0.000 description 10
• 238000009169 immunotherapy Methods 0.000 description 10
• 239000000243 solution Substances 0.000 description 10
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
• 239000004480 active ingredient Substances 0.000 description 9
• 239000000969 carrier Substances 0.000 description 9
• 229950009791 durvalumab Drugs 0.000 description 9
• 206010018338 Glioma Diseases 0.000 description 8
• 230000037396 body weight Effects 0.000 description 8
• 239000003937 drug carrier Substances 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• 206010061289 metastatic neoplasm Diseases 0.000 description 8
• 239000006186 oral dosage form Substances 0.000 description 8
• 102000005962 receptors Human genes 0.000 description 8
• 108020003175 receptors Proteins 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• 206010003571 Astrocytoma Diseases 0.000 description 7
• 241000699670 Mus sp. Species 0.000 description 7
• 206010035226 Plasma cell myeloma Diseases 0.000 description 7
• 230000004663 cell proliferation Effects 0.000 description 7
• 230000001394 metastastic effect Effects 0.000 description 7
• 230000001575 pathological effect Effects 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 239000003981 vehicle Substances 0.000 description 7
• 208000032612 Glial tumor Diseases 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 6
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
• 230000033115 angiogenesis Effects 0.000 description 6
• 230000000259 anti-tumor effect Effects 0.000 description 6
• 238000002512 chemotherapy Methods 0.000 description 6
• 239000003085 diluting agent Substances 0.000 description 6
• 239000006185 dispersion Substances 0.000 description 6
• 230000028993 immune response Effects 0.000 description 6
• 230000002401 inhibitory effect Effects 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 210000001519 tissue Anatomy 0.000 description 6
• 102000008096 B7-H1 Antigen Human genes 0.000 description 5
• 108010074708 B7-H1 Antigen Proteins 0.000 description 5
• 208000003174 Brain Neoplasms Diseases 0.000 description 5
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
• 230000002411 adverse Effects 0.000 description 5
• 239000011230 binding agent Substances 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 210000003236 esophagogastric junction Anatomy 0.000 description 5
• 239000008187 granular material Substances 0.000 description 5
• 208000014829 head and neck neoplasm Diseases 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 210000004185 liver Anatomy 0.000 description 5
• 239000000314 lubricant Substances 0.000 description 5
• 210000004072 lung Anatomy 0.000 description 5
• 230000036210 malignancy Effects 0.000 description 5
• 231100000682 maximum tolerated dose Toxicity 0.000 description 5
• 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 5
• 230000002062 proliferating effect Effects 0.000 description 5
• 238000012552 review Methods 0.000 description 5
• 239000004094 surface-active agent Substances 0.000 description 5
• 230000002195 synergetic effect Effects 0.000 description 5
• 210000004881 tumor cell Anatomy 0.000 description 5
• 230000002792 vascular Effects 0.000 description 5
• FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 4
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
• 238000011357 CAR T-cell therapy Methods 0.000 description 4
• 206010012735 Diarrhoea Diseases 0.000 description 4
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
• 208000000172 Medulloblastoma Diseases 0.000 description 4
• 206010027476 Metastases Diseases 0.000 description 4
• 206010028813 Nausea Diseases 0.000 description 4
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
• 229910019142 PO4 Inorganic materials 0.000 description 4
• 206010035664 Pneumonia Diseases 0.000 description 4
• 102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
• 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 210000001744 T-lymphocyte Anatomy 0.000 description 4
• 208000024313 Testicular Neoplasms Diseases 0.000 description 4
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 229960000548 alemtuzumab Drugs 0.000 description 4
• 230000003527 anti-angiogenesis Effects 0.000 description 4
• 229950009579 axicabtagene ciloleucel Drugs 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 206010009887 colitis Diseases 0.000 description 4
• 230000009850 completed effect Effects 0.000 description 4
• 238000013461 design Methods 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 238000003745 diagnosis Methods 0.000 description 4
• 201000004101 esophageal cancer Diseases 0.000 description 4
• 238000011156 evaluation Methods 0.000 description 4
• 206010016256 fatigue Diseases 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 208000005017 glioblastoma Diseases 0.000 description 4
• 210000002865 immune cell Anatomy 0.000 description 4
• 230000006028 immune-suppresssive effect Effects 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 229960005386 ipilimumab Drugs 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 201000005296 lung carcinoma Diseases 0.000 description 4
• 230000009401 metastasis Effects 0.000 description 4
• 201000005962 mycosis fungoides Diseases 0.000 description 4
• 201000000050 myeloid neoplasm Diseases 0.000 description 4
• 230000008693 nausea Effects 0.000 description 4
• 231100000252 nontoxic Toxicity 0.000 description 4
• 230000003000 nontoxic effect Effects 0.000 description 4
• 238000011275 oncology therapy Methods 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
• 239000010452 phosphate Substances 0.000 description 4
• 229950010773 pidilizumab Drugs 0.000 description 4
• 239000006187 pill Substances 0.000 description 4
• 108090000765 processed proteins & peptides Proteins 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 229960000714 sipuleucel-t Drugs 0.000 description 4
• 210000003491 skin Anatomy 0.000 description 4
• 239000007909 solid dosage form Substances 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 229950007137 tisagenlecleucel Drugs 0.000 description 4
• 108010078373 tisagenlecleucel Proteins 0.000 description 4
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
• 229960005486 vaccine Drugs 0.000 description 4
• 201000003076 Angiosarcoma Diseases 0.000 description 3
• 206010065869 Astrocytoma, low grade Diseases 0.000 description 3
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
• 208000018084 Bone neoplasm Diseases 0.000 description 3
• 229940045513 CTLA4 antagonist Drugs 0.000 description 3
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
• 208000009798 Craniopharyngioma Diseases 0.000 description 3
• 102000001301 EGF receptor Human genes 0.000 description 3
• 108060006698 EGF receptor Proteins 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 206010014967 Ependymoma Diseases 0.000 description 3
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 3
• 201000004066 Ganglioglioma Diseases 0.000 description 3
• 208000001258 Hemangiosarcoma Diseases 0.000 description 3
• 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 3
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
• 206010020772 Hypertension Diseases 0.000 description 3
• 102000037982 Immune checkpoint proteins Human genes 0.000 description 3
• 108091008036 Immune checkpoint proteins Proteins 0.000 description 3
• 206010023825 Laryngeal cancer Diseases 0.000 description 3
• 206010027406 Mesothelioma Diseases 0.000 description 3
• 208000003445 Mouth Neoplasms Diseases 0.000 description 3
• 208000034578 Multiple myelomas Diseases 0.000 description 3
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
• 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 3
• 206010029260 Neuroblastoma Diseases 0.000 description 3
• 201000010133 Oligodendroglioma Diseases 0.000 description 3
• 108091008606 PDGF receptors Proteins 0.000 description 3
• 208000007641 Pinealoma Diseases 0.000 description 3
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 3
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 208000015634 Rectal Neoplasms Diseases 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• 206010042674 Swelling Diseases 0.000 description 3
• 206010047700 Vomiting Diseases 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 239000003708 ampul Substances 0.000 description 3
• 208000007502 anemia Diseases 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• 201000009036 biliary tract cancer Diseases 0.000 description 3
• 208000020790 biliary tract neoplasm Diseases 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 210000000481 breast Anatomy 0.000 description 3
• 239000006189 buccal tablet Substances 0.000 description 3
• 229940046011 buccal tablet Drugs 0.000 description 3
• 239000007910 chewable tablet Substances 0.000 description 3
• 229940068682 chewable tablet Drugs 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 239000006071 cream Substances 0.000 description 3
• 239000013078 crystal Substances 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 231100000517 death Toxicity 0.000 description 3
• 239000003596 drug target Substances 0.000 description 3
• 210000002889 endothelial cell Anatomy 0.000 description 3
• 230000002708 enhancing effect Effects 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 201000010175 gallbladder cancer Diseases 0.000 description 3
• 201000006585 gastric adenocarcinoma Diseases 0.000 description 3
• 230000002496 gastric effect Effects 0.000 description 3
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 description 3
• 201000009277 hairy cell leukemia Diseases 0.000 description 3
• 201000010536 head and neck cancer Diseases 0.000 description 3
• 229940126546 immune checkpoint molecule Drugs 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 201000002313 intestinal cancer Diseases 0.000 description 3
• 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 229940043355 kinase inhibitor Drugs 0.000 description 3
• 206010023841 laryngeal neoplasm Diseases 0.000 description 3
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 3
• 239000008297 liquid dosage form Substances 0.000 description 3
• 238000004519 manufacturing process Methods 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 108700031196 mouse lisch-like Proteins 0.000 description 3
• JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 206010073131 oligoastrocytoma Diseases 0.000 description 3
• 239000006191 orally-disintegrating tablet Substances 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
• 229940023488 pill Drugs 0.000 description 3
• 229940068196 placebo Drugs 0.000 description 3
• 239000000902 placebo Substances 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000001023 pro-angiogenic effect Effects 0.000 description 3
• 201000001514 prostate carcinoma Diseases 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 206010038038 rectal cancer Diseases 0.000 description 3
• 201000001275 rectum cancer Diseases 0.000 description 3
• 230000000306 recurrent effect Effects 0.000 description 3
• 239000008299 semisolid dosage form Substances 0.000 description 3
• 239000006190 sub-lingual tablet Substances 0.000 description 3
• 229940098466 sublingual tablet Drugs 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 230000008961 swelling Effects 0.000 description 3
• 235000020357 syrup Nutrition 0.000 description 3
• 239000006188 syrup Substances 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• 230000008673 vomiting Effects 0.000 description 3
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• 208000004998 Abdominal Pain Diseases 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 206010067484 Adverse reaction Diseases 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 2
• 206010061424 Anal cancer Diseases 0.000 description 2
• 208000007860 Anus Neoplasms Diseases 0.000 description 2
• 206010060971 Astrocytoma malignant Diseases 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 description 2
• 208000003950 B-cell lymphoma Diseases 0.000 description 2
• 206010004146 Basal cell carcinoma Diseases 0.000 description 2
• 206010005949 Bone cancer Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 206010006143 Brain stem glioma Diseases 0.000 description 2
• 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 208000009458 Carcinoma in Situ Diseases 0.000 description 2
• 241000700199 Cavia porcellus Species 0.000 description 2
• 201000005262 Chondroma Diseases 0.000 description 2
• 208000005243 Chondrosarcoma Diseases 0.000 description 2
• 201000009047 Chordoma Diseases 0.000 description 2
• 208000006332 Choriocarcinoma Diseases 0.000 description 2
• 208000004378 Choroid plexus papilloma Diseases 0.000 description 2
• 206010011224 Cough Diseases 0.000 description 2
• 208000010201 Exanthema Diseases 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 208000021309 Germ cell tumor Diseases 0.000 description 2
• 208000000527 Germinoma Diseases 0.000 description 2
• 201000005409 Gliomatosis cerebri Diseases 0.000 description 2
• 206010068601 Glioneuronal tumour Diseases 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 102000003746 Insulin Receptor Human genes 0.000 description 2
• 108010001127 Insulin Receptor Proteins 0.000 description 2
• 208000007766 Kaposi sarcoma Diseases 0.000 description 2
• 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 2
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
• 206010063916 Metastatic gastric cancer Diseases 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• 208000037064 Papilloma of choroid plexus Diseases 0.000 description 2
• 206010061332 Paraganglion neoplasm Diseases 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• 206010050487 Pinealoblastoma Diseases 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 201000005746 Pituitary adenoma Diseases 0.000 description 2
• 206010061538 Pituitary tumour benign Diseases 0.000 description 2
• 206010035742 Pneumonitis Diseases 0.000 description 2
• 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 2
• 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• 201000000582 Retinoblastoma Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 208000000453 Skin Neoplasms Diseases 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• 230000005867 T cell response Effects 0.000 description 2
• 206010057644 Testis cancer Diseases 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
• 208000002495 Uterine Neoplasms Diseases 0.000 description 2
• 201000005969 Uveal melanoma Diseases 0.000 description 2
• 208000014070 Vestibular schwannoma Diseases 0.000 description 2
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
• 208000004064 acoustic neuroma Diseases 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 230000006838 adverse reaction Effects 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
• 208000008524 alveolar soft part sarcoma Diseases 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 239000000739 antihistaminic agent Substances 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• 201000011165 anus cancer Diseases 0.000 description 2
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
• 239000006172 buffering agent Substances 0.000 description 2
• 229960001292 cabozantinib Drugs 0.000 description 2
• ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
• 208000035269 cancer or benign tumor Diseases 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 201000007335 cerebellar astrocytoma Diseases 0.000 description 2
• 239000012829 chemotherapy agent Substances 0.000 description 2
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 238000011284 combination treatment Methods 0.000 description 2
• 210000004443 dendritic cell Anatomy 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 201000004428 dysembryoplastic neuroepithelial tumor Diseases 0.000 description 2
• 201000005884 exanthem Diseases 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 210000003414 extremity Anatomy 0.000 description 2
• 210000003754 fetus Anatomy 0.000 description 2
• 206010016629 fibroma Diseases 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 201000008361 ganglioneuroma Diseases 0.000 description 2
• 201000007492 gastroesophageal junction adenocarcinoma Diseases 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 201000003115 germ cell cancer Diseases 0.000 description 2
• 238000005469 granulation Methods 0.000 description 2
• 230000003179 granulation Effects 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 201000002222 hemangioblastoma Diseases 0.000 description 2
• 230000002489 hematologic effect Effects 0.000 description 2
• 231100000304 hepatotoxicity Toxicity 0.000 description 2
• XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 2
• 201000001421 hyperglycemia Diseases 0.000 description 2
• 208000006575 hypertriglyceridemia Diseases 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 230000001965 increasing effect Effects 0.000 description 2
• 238000011221 initial treatment Methods 0.000 description 2
• 206010022694 intestinal perforation Diseases 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 230000007056 liver toxicity Effects 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 210000004324 lymphatic system Anatomy 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 231100001142 manageable toxicity Toxicity 0.000 description 2
• 238000007726 management method Methods 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 229940126601 medicinal product Drugs 0.000 description 2
• 206010027191 meningioma Diseases 0.000 description 2
• 208000037819 metastatic cancer Diseases 0.000 description 2
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
• 208000037843 metastatic solid tumor Diseases 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 238000000465 moulding Methods 0.000 description 2
• 208000025113 myeloid leukemia Diseases 0.000 description 2
• 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
• 208000007538 neurilemmoma Diseases 0.000 description 2
• 201000011519 neuroendocrine tumor Diseases 0.000 description 2
• 208000027831 neuroepithelial neoplasm Diseases 0.000 description 2
• 208000004235 neutropenia Diseases 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 229940049964 oleate Drugs 0.000 description 2
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
• 201000008968 osteosarcoma Diseases 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 230000036407 pain Effects 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 208000007312 paraganglioma Diseases 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 201000003113 pineoblastoma Diseases 0.000 description 2
• 208000021310 pituitary gland adenoma Diseases 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 238000011518 platinum-based chemotherapy Methods 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• 206010037844 rash Diseases 0.000 description 2
• 210000000664 rectum Anatomy 0.000 description 2
• 210000002345 respiratory system Anatomy 0.000 description 2
• 208000037803 restenosis Diseases 0.000 description 2
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
• 206010039667 schwannoma Diseases 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 201000000849 skin cancer Diseases 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 229940032147 starch Drugs 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 201000004059 subependymal giant cell astrocytoma Diseases 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 206010042863 synovial sarcoma Diseases 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 238000002626 targeted therapy Methods 0.000 description 2
• 201000003120 testicular cancer Diseases 0.000 description 2
• YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
• 206010043554 thrombocytopenia Diseases 0.000 description 2
• 208000008732 thymoma Diseases 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• 230000005740 tumor formation Effects 0.000 description 2
• 230000002485 urinary effect Effects 0.000 description 2
• 206010046766 uterine cancer Diseases 0.000 description 2
• 210000005166 vasculature Anatomy 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
• KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
• LRMSQVBRUNSOJL-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)F LRMSQVBRUNSOJL-UHFFFAOYSA-N 0.000 description 1
• MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
• WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 1
• BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
• ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
• NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 1
• ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
• HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
• VERUFXOALATMPS-UHFFFAOYSA-N 5,5-diamino-2-(2-phenylethenyl)cyclohex-3-ene-1,1-disulfonic acid Chemical compound C1=CC(N)(N)CC(S(O)(=O)=O)(S(O)(=O)=O)C1C=CC1=CC=CC=C1 VERUFXOALATMPS-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
• 206010000050 Abdominal adhesions Diseases 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 235000006491 Acacia senegal Nutrition 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000007876 Acrospiroma Diseases 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
• 208000001783 Adamantinoma Diseases 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
• POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 1
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
• 206010002240 Anaplastic thyroid cancer Diseases 0.000 description 1
• 206010051810 Angiomyolipoma Diseases 0.000 description 1
• 206010073360 Appendix cancer Diseases 0.000 description 1
• 101100301148 Arabidopsis thaliana RCCR gene Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 208000004736 B-Cell Leukemia Diseases 0.000 description 1
• 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
• 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 206010004453 Benign salivary gland neoplasm Diseases 0.000 description 1
• KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• 208000007690 Brenner tumor Diseases 0.000 description 1
• 206010073258 Brenner tumour Diseases 0.000 description 1
• 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
• 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
• 206010070487 Brown tumour Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• 238000011740 C57BL/6 mouse Methods 0.000 description 1
• 108010069682 CSK Tyrosine-Protein Kinase Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 206010007275 Carcinoid tumour Diseases 0.000 description 1
• 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
• 201000000274 Carcinosarcoma Diseases 0.000 description 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• 208000005024 Castleman disease Diseases 0.000 description 1
• 208000003732 Cat-scratch disease Diseases 0.000 description 1
• 208000037138 Central nervous system embryonal tumor Diseases 0.000 description 1
• 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
• 206010073130 Central nervous system neuroblastoma Diseases 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 206010008583 Chloroma Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 206010052012 Congenital teratoma Diseases 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 206010011017 Corneal graft rejection Diseases 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 241000252212 Danio rerio Species 0.000 description 1
• 208000008334 Dermatofibrosarcoma Diseases 0.000 description 1
• 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 1
• 208000001154 Dermoid Cyst Diseases 0.000 description 1
• 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 1
• 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• 208000021994 Diffuse astrocytoma Diseases 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
• 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
• 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
• 208000033832 Eosinophilic Acute Leukemia Diseases 0.000 description 1
• 201000008228 Ependymoblastoma Diseases 0.000 description 1
• 206010014968 Ependymoma malignant Diseases 0.000 description 1
• 201000005231 Epithelioid sarcoma Diseases 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 208000012468 Ewing sarcoma/peripheral primitive neuroectodermal tumor Diseases 0.000 description 1
• 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
• 208000010368 Extramammary Paget Disease Diseases 0.000 description 1
• 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
• 206010015866 Extravasation Diseases 0.000 description 1
• 201000001342 Fallopian tube cancer Diseases 0.000 description 1
• 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
• CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 241000206672 Gelidium Species 0.000 description 1
• 206010061183 Genitourinary tract neoplasm Diseases 0.000 description 1
• 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 208000022461 Glomerular disease Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 206010018381 Glomus tumour Diseases 0.000 description 1
• 206010018404 Glucagonoma Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 208000005234 Granulosa Cell Tumor Diseases 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 206010066476 Haematological malignancy Diseases 0.000 description 1
• 208000006050 Hemangiopericytoma Diseases 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
• 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
• 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
• 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
• 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
• 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
• 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
• 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
• 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
• 206010061252 Intraocular melanoma Diseases 0.000 description 1
• 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 102000042838 JAK family Human genes 0.000 description 1
• 108091082332 JAK family Proteins 0.000 description 1
• 208000002260 Keloid Diseases 0.000 description 1
• 208000007666 Klatskin Tumor Diseases 0.000 description 1
• 208000000675 Krukenberg Tumor Diseases 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• 239000002139 L01XE22 - Masitinib Substances 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 206010024218 Lentigo maligna Diseases 0.000 description 1
• 241000270322 Lepidosauria Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 206010024305 Leukaemia monocytic Diseases 0.000 description 1
• 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 201000002171 Luteoma Diseases 0.000 description 1
• 206010025219 Lymphangioma Diseases 0.000 description 1
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
• 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 201000003791 MALT lymphoma Diseases 0.000 description 1
• 229940124647 MEK inhibitor Drugs 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 206010064281 Malignant atrophic papulosis Diseases 0.000 description 1
• 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
• 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 1
• 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 description 1
• 208000032271 Malignant tumor of penis Diseases 0.000 description 1
• PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
• 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
• 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
• 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
• 206010027462 Metastases to ovary Diseases 0.000 description 1
• 208000032818 Microsatellite Instability Diseases 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
• 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
• 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
• KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
• UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
• HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010028729 Nasal cavity cancer Diseases 0.000 description 1
• 206010028767 Nasal sinus cancer Diseases 0.000 description 1
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 208000008846 Neurocytoma Diseases 0.000 description 1
• 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 208000005890 Neuroma Diseases 0.000 description 1
• 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 206010029488 Nodular melanoma Diseases 0.000 description 1
• 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
• 206010048757 Oncocytoma Diseases 0.000 description 1
• 206010073338 Optic glioma Diseases 0.000 description 1
• 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
• 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
• 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
• 206010033268 Ovarian low malignant potential tumour Diseases 0.000 description 1
• 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 208000002063 Oxyphilic Adenoma Diseases 0.000 description 1
• 208000025618 Paget disease of nipple Diseases 0.000 description 1
• 206010033553 Palmar-plantar erythrodysaesthesia syndrome Diseases 0.000 description 1
• 201000010630 Pancoast tumor Diseases 0.000 description 1
• 208000015330 Pancoast tumour Diseases 0.000 description 1
• 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
• 208000003937 Paranasal Sinus Neoplasms Diseases 0.000 description 1
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 206010034299 Penile cancer Diseases 0.000 description 1
• 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 1
• 208000000360 Perivascular Epithelioid Cell Neoplasms Diseases 0.000 description 1
• 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
• 206010034811 Pharyngeal cancer Diseases 0.000 description 1
• 208000021308 Pituicytoma Diseases 0.000 description 1
• 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
• 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 1
• 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
• 208000006930 Pseudomyxoma Peritonei Diseases 0.000 description 1
• 208000034541 Rare lymphatic malformation Diseases 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 206010038934 Retinopathy proliferative Diseases 0.000 description 1
• 208000008938 Rhabdoid tumor Diseases 0.000 description 1
• 208000005678 Rhabdomyoma Diseases 0.000 description 1
• 208000025316 Richter syndrome Diseases 0.000 description 1
• 208000025280 Sacrococcygeal teratoma Diseases 0.000 description 1
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
• 206010061934 Salivary gland cancer Diseases 0.000 description 1
• 208000006938 Schwannomatosis Diseases 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 208000002669 Sex Cord-Gonadal Stromal Tumors Diseases 0.000 description 1
• 208000009359 Sezary Syndrome Diseases 0.000 description 1
• 208000021388 Sezary disease Diseases 0.000 description 1
• 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 206010041329 Somatostatinoma Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
• 208000001662 Subependymal Glioma Diseases 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
• 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
• 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
• 208000000389 T-cell leukemia Diseases 0.000 description 1
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
• 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
• 239000005463 Tandutinib Substances 0.000 description 1
• 229920002253 Tannate Polymers 0.000 description 1
• 241000255588 Tephritidae Species 0.000 description 1
• 206010043276 Teratoma Diseases 0.000 description 1
• GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
• 201000000331 Testicular germ cell cancer Diseases 0.000 description 1
• 206010043515 Throat cancer Diseases 0.000 description 1
• 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
• 201000009365 Thymic carcinoma Diseases 0.000 description 1
• 102000003929 Transaminases Human genes 0.000 description 1
• 108090000340 Transaminases Proteins 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
• 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 206010046431 Urethral cancer Diseases 0.000 description 1
• 206010046458 Urethral neoplasms Diseases 0.000 description 1
• 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
• 229940124304 VEGF/VEGFR inhibitor Drugs 0.000 description 1
• 208000009311 VIPoma Diseases 0.000 description 1
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
• 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 206010047741 Vulval cancer Diseases 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• 208000021146 Warthin tumor Diseases 0.000 description 1
• 208000000260 Warts Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 208000012018 Yolk sac tumor Diseases 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 239000003655 absorption accelerator Substances 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 206010059394 acanthoma Diseases 0.000 description 1
• 230000035508 accumulation Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 159000000021 acetate salts Chemical class 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• KQNKJJBFUFKYFX-UHFFFAOYSA-N acetic acid;trihydrate Chemical compound O.O.O.CC(O)=O KQNKJJBFUFKYFX-UHFFFAOYSA-N 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 208000006336 acinar cell carcinoma Diseases 0.000 description 1
• 206010000583 acral lentiginous melanoma Diseases 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
• 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
• 208000026784 acute myeloblastic leukemia with maturation Diseases 0.000 description 1
• 230000003044 adaptive effect Effects 0.000 description 1
• 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
• 208000026562 adenomatoid odontogenic tumor Diseases 0.000 description 1
• 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
• 239000003470 adrenal cortex hormone Substances 0.000 description 1
• 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
• 239000003463 adsorbent Substances 0.000 description 1
• 201000006966 adult T-cell leukemia Diseases 0.000 description 1
• 208000037844 advanced solid tumor Diseases 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 229960002833 aflibercept Drugs 0.000 description 1
• 108010081667 aflibercept Proteins 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 208000015230 aggressive NK-cell leukemia Diseases 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 229960000458 allantoin Drugs 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 230000002707 ameloblastic effect Effects 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 229950003153 amsonate Drugs 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
• 239000002870 angiogenesis inducing agent Substances 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 230000001772 anti-angiogenic effect Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000001387 anti-histamine Effects 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000005809 anti-tumor immunity Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 229940125715 antihistaminic agent Drugs 0.000 description 1
• 239000003430 antimalarial agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 238000003782 apoptosis assay Methods 0.000 description 1
• 208000021780 appendiceal neoplasm Diseases 0.000 description 1
• 230000004594 appetite change Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 229960003121 arginine Drugs 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• OISFUZRUIGGTSD-LJTMIZJLSA-N azane;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound N.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-N 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 229960003237 betaine Drugs 0.000 description 1
• 229960000397 bevacizumab Drugs 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 238000005842 biochemical reaction Methods 0.000 description 1
• 239000003124 biologic agent Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 201000009076 bladder urachal carcinoma Diseases 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 201000011143 bone giant cell tumor Diseases 0.000 description 1
• 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 208000002458 carcinoid tumor Diseases 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 230000034303 cell budding Effects 0.000 description 1
• 230000034196 cell chemotaxis Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 201000007455 central nervous system cancer Diseases 0.000 description 1
• 201000010702 central neurocytoma Diseases 0.000 description 1
• 208000030239 cerebral astrocytoma Diseases 0.000 description 1
• 201000001403 cerebral neuroblastoma Diseases 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 230000000739 chaotic effect Effects 0.000 description 1
• 230000001767 chemoprotection Effects 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 239000000812 cholinergic antagonist Substances 0.000 description 1
• 208000006571 choroid plexus carcinoma Diseases 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 201000006778 chronic monocytic leukemia Diseases 0.000 description 1
• 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 208000013056 classic Hodgkin lymphoma Diseases 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 201000010276 collecting duct carcinoma Diseases 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 201000010918 connective tissue cancer Diseases 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001681 croscarmellose sodium Drugs 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 208000017563 cutaneous Paget disease Diseases 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 208000030263 desmoplastic infantile astrocytoma Diseases 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
• SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
• 239000001177 diphosphate Substances 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
• 230000007783 downstream signaling Effects 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 229940088679 drug related substance Drugs 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 238000010410 dusting Methods 0.000 description 1
• 229940009662 edetate Drugs 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 208000001991 endodermal sinus tumor Diseases 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 208000027858 endometrioid tumor Diseases 0.000 description 1
• 230000010595 endothelial cell migration Effects 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 231100000321 erythema Toxicity 0.000 description 1
• 208000032099 esthesioneuroblastoma Diseases 0.000 description 1
• 229950000206 estolate Drugs 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 235000019441 ethanol Nutrition 0.000 description 1
• 150000002169 ethanolamines Chemical class 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
• 230000036251 extravasation Effects 0.000 description 1
• 208000024519 eye neoplasm Diseases 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 201000010972 female reproductive endometrioid cancer Diseases 0.000 description 1
• 201000001169 fibrillary astrocytoma Diseases 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000009093 first-line therapy Methods 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 230000009246 food effect Effects 0.000 description 1
• 235000021471 food effect Nutrition 0.000 description 1
• 150000004675 formic acid derivatives Chemical class 0.000 description 1
• 229940050411 fumarate Drugs 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 201000005649 gangliocytoma Diseases 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 201000011587 gastric lymphoma Diseases 0.000 description 1
• 230000014509 gene expression Effects 0.000 description 1
• 201000008822 gestational choriocarcinoma Diseases 0.000 description 1
• 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
• 229960001731 gluceptate Drugs 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 229960002442 glucosamine Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 229940049906 glutamate Drugs 0.000 description 1
• 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 208000003064 gonadoblastoma Diseases 0.000 description 1
• 239000003979 granulating agent Substances 0.000 description 1
• 230000003676 hair loss Effects 0.000 description 1
• 208000024963 hair loss Diseases 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 201000003911 head and neck carcinoma Diseases 0.000 description 1
• 201000010235 heart cancer Diseases 0.000 description 1
• 208000024348 heart neoplasm Diseases 0.000 description 1
• 206010066957 hepatosplenic T-cell lymphoma Diseases 0.000 description 1
• 201000011045 hereditary breast ovarian cancer syndrome Diseases 0.000 description 1
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• 208000029824 high grade glioma Diseases 0.000 description 1
• 208000018060 hilar cholangiocarcinoma Diseases 0.000 description 1
• 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 229940125697 hormonal agent Drugs 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 230000003463 hyperproliferative effect Effects 0.000 description 1
• 201000006866 hypopharynx cancer Diseases 0.000 description 1
• 230000002267 hypothalamic effect Effects 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• 208000003532 hypothyroidism Diseases 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 230000008629 immune suppression Effects 0.000 description 1
• 230000037451 immune surveillance Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 230000001024 immunotherapeutic effect Effects 0.000 description 1
• 201000004933 in situ carcinoma Diseases 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
• 238000007915 intraurethral administration Methods 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• 201000002529 islet cell tumor Diseases 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 230000009916 joint effect Effects 0.000 description 1
• 201000000573 juvenile pilocytic astrocytoma Diseases 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 210000001117 keloid Anatomy 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 229940099584 lactobionate Drugs 0.000 description 1
• JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
• 201000004962 larynx cancer Diseases 0.000 description 1
• 229940070765 laurate Drugs 0.000 description 1
• 208000011080 lentigo maligna melanoma Diseases 0.000 description 1
• 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
• 238000009092 lines of therapy Methods 0.000 description 1
• 229950002216 linifanib Drugs 0.000 description 1
• MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 description 1
• 210000000088 lip Anatomy 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 235000014666 liquid concentrate Nutrition 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 229910003002 lithium salt Inorganic materials 0.000 description 1
• 159000000002 lithium salts Chemical class 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
• 208000024169 luteoma of pregnancy Diseases 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 208000012804 lymphangiosarcoma Diseases 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 208000003747 lymphoid leukemia Diseases 0.000 description 1
• 201000000564 macroglobulinemia Diseases 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 150000002688 maleic acid derivatives Chemical class 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 208000030883 malignant astrocytoma Diseases 0.000 description 1
• 201000011614 malignant glioma Diseases 0.000 description 1
• 208000006178 malignant mesothelioma Diseases 0.000 description 1
• 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
• 208000015179 malignant superior sulcus neoplasm Diseases 0.000 description 1
• 201000001117 malignant triton tumor Diseases 0.000 description 1
• 208000026037 malignant tumor of neck Diseases 0.000 description 1
• 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
• 208000027202 mammary Paget disease Diseases 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• 229910052748 manganese Inorganic materials 0.000 description 1
• 239000011572 manganese Substances 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 229960004655 masitinib Drugs 0.000 description 1
• WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 description 1
• 208000000516 mast-cell leukemia Diseases 0.000 description 1
• 201000000349 mediastinal cancer Diseases 0.000 description 1
• 208000029586 mediastinal germ cell tumor Diseases 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
• 201000008203 medulloepithelioma Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 208000011645 metastatic carcinoma Diseases 0.000 description 1
• 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
• 229940102396 methyl bromide Drugs 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
• JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
• 210000004088 microvessel Anatomy 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
• 230000033607 mismatch repair Effects 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 201000004058 mixed glioma Diseases 0.000 description 1
• 239000007932 molded tablet Substances 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 201000006894 monocytic leukemia Diseases 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 208000022669 mucinous neoplasm Diseases 0.000 description 1
• 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
• 231100000219 mutagenic Toxicity 0.000 description 1
• 230000003505 mutagenic effect Effects 0.000 description 1
• 201000005987 myeloid sarcoma Diseases 0.000 description 1
• 208000009091 myxoma Diseases 0.000 description 1
• 208000026721 nail disease Diseases 0.000 description 1
• 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 208000018280 neoplasm of mediastinum Diseases 0.000 description 1
• 208000028732 neoplasm with perivascular epithelioid cell differentiation Diseases 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 201000003142 neovascular glaucoma Diseases 0.000 description 1
• 201000009925 nephrosclerosis Diseases 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 201000009494 neurilemmomatosis Diseases 0.000 description 1
• 208000029974 neurofibrosarcoma Diseases 0.000 description 1
• 235000005152 nicotinamide Nutrition 0.000 description 1
• 239000011570 nicotinamide Substances 0.000 description 1
• DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 201000000032 nodular malignant melanoma Diseases 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 239000007764 o/w emulsion Substances 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 201000008106 ocular cancer Diseases 0.000 description 1
• 201000002575 ocular melanoma Diseases 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 208000008511 optic nerve glioma Diseases 0.000 description 1
• 201000011130 optic nerve sheath meningioma Diseases 0.000 description 1
• 208000022982 optic pathway glioma Diseases 0.000 description 1
• 201000005443 oral cavity cancer Diseases 0.000 description 1
• 239000007935 oral tablet Substances 0.000 description 1
• 229950006354 orantinib Drugs 0.000 description 1
• 201000006958 oropharynx cancer Diseases 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• 229940124641 pain reliever Drugs 0.000 description 1
• 238000002638 palliative care Methods 0.000 description 1
• 201000011116 pancreatic cholera Diseases 0.000 description 1
• 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
• 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
• 229940014662 pantothenate Drugs 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 239000011713 pantothenic acid Substances 0.000 description 1
• 208000003154 papilloma Diseases 0.000 description 1
• 208000029211 papillomatosis Diseases 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 201000007052 paranasal sinus cancer Diseases 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 208000030940 penile carcinoma Diseases 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 201000005207 perivascular epithelioid cell tumor Diseases 0.000 description 1
• 229940127557 pharmaceutical product Drugs 0.000 description 1
• 230000002974 pharmacogenomic effect Effects 0.000 description 1
• 210000003800 pharynx Anatomy 0.000 description 1
• 208000028591 pheochromocytoma Diseases 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• 201000004119 pineal parenchymal tumor of intermediate differentiation Diseases 0.000 description 1
• 206010035059 pineocytoma Diseases 0.000 description 1
• 208000010916 pituitary tumor Diseases 0.000 description 1
• 208000010626 plasma cell neoplasm Diseases 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 229920000768 polyamine Polymers 0.000 description 1
• 208000024246 polyembryoma Diseases 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000005033 polyvinylidene chloride Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 235000014483 powder concentrate Nutrition 0.000 description 1
• 238000012910 preclinical development Methods 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 238000003672 processing method Methods 0.000 description 1
• 230000005522 programmed cell death Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 201000001474 proteinuria Diseases 0.000 description 1
• 101150020896 ptk gene Proteins 0.000 description 1
• 239000008213 purified water Substances 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 150000003222 pyridines Chemical class 0.000 description 1
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
• CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 description 1
• 229950001626 quizartinib Drugs 0.000 description 1
• 230000004223 radioprotective effect Effects 0.000 description 1
• 229960002633 ramucirumab Drugs 0.000 description 1
• 229960003876 ranibizumab Drugs 0.000 description 1
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 210000003289 regulatory T cell Anatomy 0.000 description 1
• 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
• 210000004994 reproductive system Anatomy 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000008261 resistance mechanism Effects 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
• 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
• DFJSJLGUIXFDJP-UHFFFAOYSA-N sapitinib Chemical compound C1CN(CC(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F DFJSJLGUIXFDJP-UHFFFAOYSA-N 0.000 description 1
• 229950006474 sapitinib Drugs 0.000 description 1
• 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
• 238000011519 second-line treatment Methods 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 208000011581 secondary neoplasm Diseases 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 208000026775 severe diarrhea Diseases 0.000 description 1
• 208000028467 sex cord-stromal tumor Diseases 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 235000020374 simple syrup Nutrition 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 201000008261 skin carcinoma Diseases 0.000 description 1
• 201000010153 skin papilloma Diseases 0.000 description 1
• 208000000649 small cell carcinoma Diseases 0.000 description 1
• 201000002314 small intestine cancer Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 239000004071 soot Substances 0.000 description 1
• 206010062261 spinal cord neoplasm Diseases 0.000 description 1
• 208000037959 spinal tumor Diseases 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
• 230000003637 steroidlike Effects 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 208000030819 subependymoma Diseases 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 150000008054 sulfonate salts Chemical class 0.000 description 1
• 229940071103 sulfosalicylate Drugs 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• KUNICNFETYAKKO-UHFFFAOYSA-N sulfuric acid;pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O KUNICNFETYAKKO-UHFFFAOYSA-N 0.000 description 1
• 208000030457 superficial spreading melanoma Diseases 0.000 description 1
• 230000003319 supportive effect Effects 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000009747 swallowing Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 238000009121 systemic therapy Methods 0.000 description 1
• UXXQOJXBIDBUAC-UHFFFAOYSA-N tandutinib Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(OC(C)C)=CC=3)N=CN=C2C=C1OCCCN1CCCCC1 UXXQOJXBIDBUAC-UHFFFAOYSA-N 0.000 description 1
• 229950009893 tandutinib Drugs 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 150000003892 tartrate salts Chemical class 0.000 description 1
• 229950002757 teoclate Drugs 0.000 description 1
• 150000003512 tertiary amines Chemical class 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 208000001644 thecoma Diseases 0.000 description 1
• 229960004559 theobromine Drugs 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
• 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
• 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 1
• 210000002105 tongue Anatomy 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000440 toxicity profile Toxicity 0.000 description 1
• 201000007363 trachea carcinoma Diseases 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 210000004981 tumor-associated macrophage Anatomy 0.000 description 1
• 238000007492 two-way ANOVA Methods 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 1
• 208000037965 uterine sarcoma Diseases 0.000 description 1
• 206010046885 vaginal cancer Diseases 0.000 description 1
• 208000013139 vaginal neoplasm Diseases 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 208000008662 verrucous carcinoma Diseases 0.000 description 1
• 230000007998 vessel formation Effects 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1